Cryopreserved Platelets (CPP) for US FDA Licensure

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

ARMY MED RES ACQ ACTIVITY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9427-26-RFI-705

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

Frederick, Maryland, UNITED STATES

SourceSAM
Documents2
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Sources Sought notice (Procurement Identifier: HT9427-26-RFI-705) seeking information from potential commercial partners regarding the development and management of cryopreserved platelets (CPP) for US FDA licensure. This initiative is led by the Army Medical Research Acquisition Activity (AMRAA), with the place of performance specified as Frederick, Maryland. The primary objective of this procurement activity is to advance a biologic product—Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP)—which is being developed by OPMED’s WPAC PMO. The DMSO CPP is a frozen, biologic-platelet product designed to significantly extend the shelf life of platelets used in medical settings. Unlike liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20°C to 24°C) under gentle agitation, the DMSO CPP aims to provide a platelet-derived product with a shelf life of two years or potentially longer. This extended shelf life is intended to enhance medical readiness and improve the quality of life for active-duty personnel, particularly in operational environments where access to fresh platelets may be limited. The scope of this notice encompasses research and development activities in the physical, engineering, and life sciences, as classified under NAICS Code 541715 (2022 version). The DHA is seeking to collaborate directly with commercial partners who possess the capability to support the development, regulatory approval, and potential production of this innovative biologic product. The intended outcome is to secure US FDA licensure for DMSO CPP, thereby enabling its deployment to protect and sustain the Warfighter. Key requirements and expected deliverables include expertise in biologic product development, familiarity with FDA regulatory pathways, and the ability to support the transition of CPP from research to operational use. Respondents should demonstrate relevant experience in research and development within the life sciences, particularly in the area of biologic products for medical use. This notice is a Sources Sought announcement, not a solicitation for proposals. It is intended to gather information from interested parties to inform future procurement strategies. There are no set-aside requirements or special considerations specified at this stage. Contractors evaluating this opportunity should note that the core elements—development of DMSO CPP, FDA licensure, and support for military medical readiness—will remain constant throughout the contract lifecycle. The contracting entity is the Army Medical Research Acquisition Activity, a federal office within the Defense Health Agency. Interested parties may direct inquiries or submit responses to the primary contact, Peter Mitchell ([email protected]), or the secondary contact, Kelly Green ([email protected]). The notice remains active, with a response deadline of May 4, 2026. Additional information and attachments are available via the official SAM.gov opportunity listing (Opportunity ID: e2c26dc3937049faa715f6fa7fad2308). Contractors with relevant capabilities in biologic product development and regulatory affairs are encouraged to review the notice and consider responding to support this critical initiative for military medical readiness.